机构:[1]Department of Thoracic Oncology, Cancer Center, West China Hospital, Huaxi,Sichuan University, Chengdu, China四川大学华西医院[2]Department of Thoracic Oncology, CancerCenter, State Key Laboratory of Biotherapy, West China Hospital, Huaxi, SichuanUniversity, Chengdu, China四川大学华西医院[3]Lung Cancer Medical Oncology, Sichuan CancerHospital, Chengdu, China四川省肿瘤医院
第一作者机构:[1]Department of Thoracic Oncology, Cancer Center, West China Hospital, Huaxi,Sichuan University, Chengdu, China
推荐引用方式(GB/T 7714):
Hongmei L.,Huang M.,Xu Y.,et al.Clinical analysis of continuing crizotinib treatment beyond disease progression in ALK-positive non-small-cell lung cancer patients[J].ANNALS OF ONCOLOGY.2016,27:doi:10.1093/annonc/mdw383.66.
APA:
Hongmei, L.,Huang, M.,Xu, Y.,Zhou, X.,Li, J....&Lu, Y..(2016).Clinical analysis of continuing crizotinib treatment beyond disease progression in ALK-positive non-small-cell lung cancer patients.ANNALS OF ONCOLOGY,27,
MLA:
Hongmei, L.,et al."Clinical analysis of continuing crizotinib treatment beyond disease progression in ALK-positive non-small-cell lung cancer patients".ANNALS OF ONCOLOGY 27.(2016)